Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Abstract
New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs.
我要评论
本期排行
- Two cases of transfusion-trans...
- American Cancer Society, Ameri...
- HER2 gene amplification in bre...
- Plasma-diluted thrombin time t...
- A massive transfusion protocol...
- The evolving landscape for pat...
- Association of JAK2 mutation s...
- Comparison of methods for prol...
- Challenges and opportunities i...
- Monoallelic and biallelic dele...
共0条评论